2018 -2025 Chief Executive Officer, President and Board Member @
2019 -2025 Member Board of Trustees @
2016 -2018 Chief Operating Officer @
2011 -2016 Chief Business Officer @ Igenica Biotherapeutics
2003 -2011 Vice President, Business Development @ ArQule, Inc.
2001 -2003 Director, Business Development @ Cyclis Pharmaceuticals
2000 -2001 Senior Financial Analyst and New Ventures @
1999 -1999 Finance and Business Development Intern @
1995 -1998 Research Associate @
John Celebi Education
Carnegie Mellon University
Master of Business Administration (Business)
1998-2000
University of California - San Diego
Bachelor of Science (Biophysics)
1990-1995
Menlo School
John Celebi Skills
Drug Discovery
Biotechnology
Leadership
Corporate Development
Drug Development
Business Development
Immunology
Lifesciences
Pharmaceutical Industry
Clinical Development
Biopharmaceuticals
Oncology
Clinical Trials
Technology Transfer
Biochemistry
Clinical Research
Strategy
Commercialization
Molecular Biology
R&D
CRO
Protein Chemistry
Executive Management
Life Sciences
Research and Development (R&D)
John Celebi Summary
John Celebi, based in Boston, MA, US, is currently a Chief Executive Officer at Egle Therapeutics. John Celebi brings experience from previous roles at Sensei Bio, Washington Montessori School, X4 Pharmaceuticals and Igenica Biotherapeutics. John Celebi holds a 1998 - 2000 Master of Business Administration in Business @ Carnegie Mellon University. With a robust skill set that includes Drug Discovery, Biotechnology, Leadership, Corporate Development, Drug Development and more. John Celebi has 2 emails and 1 mobile phone numbers on RocketReach.
Get contact details of over 700M profiles across 60M companies - all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.